Jasper Therapeutics Upcoming Investor Conferencs - September 2024
Jasper Therapeutics to Showcase Innovations at September Events
Jasper Therapeutics, Inc. (NASDAQ: JSPR), a pioneer in biotechnology, is gearing up for a series of investor conferences this September. With a focus on briquilimab, a groundbreaking antibody therapy aimed at treating c-Kit (CD117) driven mast cell diseases, such as chronic spontaneous urticaria (CSU) and asthma, Jasper is excited to share its advancements and insights.
Key Conference Details
Jasper Therapeutics will participate in three notable investor conferences:
H.C. Wainwright 26th Annual Global Investment Conference
This prominent event will take place from September 9-11, 2024, with Jasper's presentation scheduled for September 10, at 3:00 p.m. ET. The format will be a fireside chat, providing an intimate setting for direct engagement with Jasper's leadership.
2024 Cantor Fitzgerald Healthcare Conference
Following H.C. Wainwright, Jasper will participate in the Cantor Fitzgerald Healthcare Conference from September 17 to 19, 2024. Jasper's presentation is set for September 17 at 2:30 p.m. ET, again formatted as a fireside chat, ensuring a responsive interaction for attending investors.
TD Cowen Chronic Urticaria Summit
The last of the series will be at the TD Cowen Chronic Urticaria Summit, with the conference happening on September 20, 2024. Jasper will present at noon ET, offering more insights into the promising results from their clinical research.
Accessing Presentations
For those interested in the presentations, live webcasts will be available on Jasper’s Investor Relations site. Additionally, an archived replay will be accessible for a limited time following the live event, ensuring that more individuals can keep up with Jasper's innovations.
About Jasper Therapeutics
Jasper is a clinical-stage biotechnology company committed to transforming the treatment landscape for patients with chronic mast and stem cell diseases through briquilimab. This monoclonal antibody specifically targets c-Kit (CD117) and is pivotal for patients suffering from conditions such as chronic urticaria, asthma, and myelodysplastic syndromes (MDS). Briquilimab has demonstrated safety and efficacy in clinical trials involving over 145 participants. Furthermore, it serves as a conditioning agent for stem cell transplants, offering hope for individuals battling rare diseases.
Company’s Commitment to Innovation
Jasper continues to push forward in clinical development, unveiling data that highlights the benefits of briquilimab as it journeys through trials. Its ability to enhance patient outcomes for conditions like acute myeloid leukemia and severe combined immunodeficiency is pivotal. The ongoing research is integral to elevating standards of care in these challenging medical arenas.
Frequently Asked Questions
1. What is briquilimab?
Briquilimab is a monoclonal antibody developed by Jasper Therapeutics targeting c-Kit (CD117), aiming to treat mast cell diseases.
2. How effective is briquilimab in clinical trials?
Briquilimab has shown a promising safety and efficacy profile in over 145 trial participants, addressing several complex conditions.
3. When and where will Jasper’s presentations occur?
Jasper will present at three conferences in September 2024, the key details are shared in the article above.
4. Can I watch the presentations online?
Yes, live webcasts of the presentations will be available on Jasper’s Investor Relations website, with archived replays following the events.
5. Who should I contact for more information?
For investor inquiries, you can reach out to Joyce Allaire at LifeSci Advisors or Alex Gray at Jasper Therapeutics, both listed in the original article.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Docusign's Upcoming Earnings: Anticipating AI-Driven Growth
- Mastercard's Impressive Growth: A 15-Year Journey to Wealth
- Investing in Centene: A 15-Year Journey of Growth
- T-Mobile US: A Decade of Remarkable Investment Growth
- Investing in Ross Stores: A 15-Year Journey of Gains
- LendingClub's Strong Buy Upgrade: Implications for Investors
- Serina Therapeutics to Showcase Innovation at Upcoming Conference
- How the Rating Boost Will Benefit Build-A-Bear Investors
- Investors Encouraged to Join Indivior PLC Class Action Lawsuit
- XPEL Investors Encouraged to Join Class Action Lawsuit
- Investors Can Lead Lawsuit Against Methode Electronics, Inc.
- International Flavors Soars to 52-Week High: Key Drivers Behind This Surge
- Corcept Therapeutics: Stock Surge and Future Prospects
- Fortive Corp Plans Strategic Spin-Off of Precision Technologies
- GM to Introduce Hybrid-Flex Vehicles in Brazil Soon
- Why Investors Are Eyeing Pearson as a Top Investment Choice
- Micron Technology's Stock Volatility: An Investor's Guide
- Nvidia Reassures Investors Amid DOJ Inquiry Uncertainty
- XPO Announces August 2024 LTL Performance Metrics
- Thunder Power Publishes Second Quarter 2024 Earnings Results
- 17EdTech Reports Q2 2024 Financial Results and Insights
- Couche-Tard Delivers Solid Revenue Growth in Q1 FY2025
- Investigation into iLearningEngines, Inc. Opens for AILE Investors
- Laser Photonics Corporation: 2024 Shareholder Meeting Highlights
- Outset Medical Investors Face Critical Deadline Ahead of Lawsuit
Recent Articles
- Kayne Anderson Energy Infrastructure Fund Updates Key Financials
- Serina Therapeutics to Showcase Innovation at Upcoming Conference
- Why Investors Are Eyeing Pearson as a Top Investment Choice
- AIGrid Supercomputing Launch on TBAA Exchange Ignites Change
- Rising Copper Demand Sparks Global Theft and Violence Issues
- General Dynamics Secures $491.6 Million Space Program Contract
- Sportsman's Warehouse Reports Q2 Sales Dip, Highlights Strategy
- US Steel Faces Challenges as Biden Might Block Major Merger
- Greif, Inc. Enhances Operations with New Facility in Malaysia
- Jason Robins to Speak at Bank of America Gaming Conference
- Jamie Mullarkey Takes On Global Role at Markel for Property Lines
- MiMedx Under Scrutiny as Counterclaims Reveal Allegations
- Shengfeng Development Announces Strong Growth for First Half 2024
- Investors Can Lead Ford Securities Fraud Class Action
- SS&C Technologies Announces Details for 2024 Analyst Day
- CrowdStrike's Growth Amid Cybersecurity Challenges
- U.S. Construction Spending Shows Unexpected Decline in June
- Bank of England Reduces Rates, Signals Cautious Future Moves
- VISIT DENVER's 'Boredom is Fired' Workforce Initiative Launch
- Invest in Justice: Lead the Ardelyx, Inc. Lawsuit Today
- Energywell Partners with Branch Energy for Sustainable Solutions
- Jim Cramer Discusses Crypto Market's Current Downturn
- Registration Now Open for Inaugural Global Compass Event
- Pixalate's Q2 2024 Ad Fraud Insights for Mobile Apps
- Federal Data Shows Progress on Bridge Repairs Nationwide